Atea Pharmaceuticals (NASDAQ: AVIR) recently reported phase 2 results for its oral SARS-CoV-2 treatment, AT-527, and the data look promising: AT-527 may offer a convenient, effective treatment to prevent disease progression both in and out of the hospital. If Atea is able to earn regulatory approval for the therapy, it should prove quite profitable for the company and its investors. It's an opportune moment for Atea to be delivering such news.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting